Recovery Act Limited Competition: Research On Biosamples From Selected Diabetes Clinical Studies (RC4)

archived

Purpose. This NIH Funding Opportunity Announcement (FOA), supported by funds provided to the NIH under the American Recovery and Reinvestment Act of 2009 (Recovery Act or ARRA), Public Law 111-5, invites applicants to apply for: 1) Access to non-renewable (non- DNA) samples generated by selected NIDDK-funded clinical trials and studies and funding to perform validated laboratory assays on the requested samples; OR 2) To apply for funding for assays to be performed on non-renewable (non- DNA) samples generated by selected NIDDK-funded clinical trials and studies, with proof of access approved by the consortia. Samples and funding will not be provided for assay development or exploratory research with animal models, or any research utilizing samples other than those that derive from studies listed below. Investigators should propose to test scientifically meritorious hypotheses related to the clinical trial or studys goals, and within the intent of the signed consent form for each study or trial. Data generated under this FOA is expected to be returned to the consortium or NIDDK repository. Mechanism of Support. This FOA will utilize the RC4 grant mechanism. Funds Available and Anticipated Number of Awards. NIDDK intends to commit up to $3,000,000 under this FOA. We anticipate that 5-10 awards will be made for fiscal year 2010, pending the number and quality of applications and availability of funds.

High